PMID- 35087406
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220129
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for 
      the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online 
      Patient Reviews.
PG  - 792877
LID - 10.3389/fphar.2021.792877 [doi]
LID - 792877
AB  - The aim of this study was to analyze the potential adverse events (AEs) caused by 
      Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, and 
      upadacitinib, used to treat rheumatoid arthritis using spontaneous AE reports 
      from the FDA (FAERS) and interpreting them in correlation with those from Korea 
      (KAERS) and an online patient review (WebMD). Potential AEs were identified based 
      on a disproportionality analysis using the proportional reporting ratio (PRR), 
      reporting odds ratio (ROR), and the information component (IC). A total of 23,720 
      reports were analyzed from FAERS database, of which 91.5% were reports on 
      tofacitinib. Potentially important medical AEs related to infections were 
      reported frequently, as well as thromboembolism-related AEs. The AEs, such as 
      malignancy, interstitial lung diseases, myocardial infarction, and 
      gastrointestinal disorder, also reported. In an online patient review report, the 
      ineffectiveness of the drug and gastrointestinal AEs were frequently reported. 
      Infection with baricitinib and symptoms related to pain or edema due to 
      upadacitinib were the main discomfort experienced by patients. In conclusion, the 
      results of this study highlight the possible safety issues associated with JAK 
      inhibitors. Routine clinical observations and further research using various 
      real-world databases are needed.
CI  - Copyright (c) 2022 Song, Song, Kim and Kwon.
FAU - Song, Yun-Kyoung
AU  - Song YK
AD  - College of Pharmacy, Daegu Catholic University, Gyeongsan, South Korea.
FAU - Song, Junu
AU  - Song J
AD  - Department of Computer Science, Viterbi School of Engineering, University of 
      Southern California, Los Angeles, CA, United States.
FAU - Kim, Kyungim
AU  - Kim K
AD  - College of Pharmacy, Korea University, Sejong, South Korea.
AD  - Institute of Pharmaceutical Science, Korea University, Sejong, South Korea.
FAU - Kwon, Jin-Won
AU  - Kwon JW
AD  - BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, 
      College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook 
      National University, Daegu, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20220111
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8787189
OTO - NOTNLM
OT  - Janus kinase inhibitors
OT  - adverse event reporting systems
OT  - online patient reviews
OT  - potential adverse events
OT  - rheumatoid arthritis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/29 06:00
MHDA- 2022/01/29 06:01
PMCR- 2022/01/11
CRDT- 2022/01/28 05:53
PHST- 2021/10/11 00:00 [received]
PHST- 2021/12/22 00:00 [accepted]
PHST- 2022/01/28 05:53 [entrez]
PHST- 2022/01/29 06:00 [pubmed]
PHST- 2022/01/29 06:01 [medline]
PHST- 2022/01/11 00:00 [pmc-release]
AID - 792877 [pii]
AID - 10.3389/fphar.2021.792877 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Jan 11;12:792877. doi: 10.3389/fphar.2021.792877. 
      eCollection 2021.